公开(公告)号：EP0625197B1

公开(公告)日：2002-12-04

申请号：EP93902110.1

申请日：1993-01-25

申请人： SYMBICOM AB

发明人： HANSSON, Lennart ,  STRÖMQVIST, Mats ,  BERGSTRÖM, Sven ,  HERNELL, Olle ,  TÖRNELL, Jan

IPC分类号： C12N15/12 ,  C12N15/85 ,  C07K14/435

CPC分类号： C12N15/8509 ,  A01K67/0278 ,  A01K2207/15 ,  A01K2217/00 ,  A01K2227/10 ,  A01K2227/101 ,  A01K2227/105 ,  A01K2267/01 ,  A23C9/20 ,  C07K14/4732 ,  C12N15/85 ,  C12N2830/002 ,  C12N2830/85 ,  C12N2840/44

摘要： The present invention relates to an expression system comprising a DNA sequence encoding a polypeptide which has a biological activity of human λ-casein, the system comprising a 5'-flanking sequence capable of mediating expression of said DNA sequence. In preferred embodiments the 5'-flanking sequence is from a milk protein gene of a mammal such as a casein gene or whey acidic protein (WAP) gene and the DNA sequence contains at least one intron sequence. The invention further relates to DNA sequences, replicable expression vectors and cells harbouring said vectors, recombinant polypeptide e.g. in glycosylated form, and milk, infant formula or nutrient supplement comprising recombinant polypeptide. The invention also relates to a method for producing a transgenic non-human mammal comprising injecting an expression system as defined above and optionally a further DNA encoding β-casein or an analogue, variant or subsequence thereof into a fertilized egg or a cell of an embryo of a mammal so as to incorporate the expression system into the germline of the mammal and developing the resulting injected fertilized egg or embryo into an adult female mammal. In one embodiment, the endogenous polypeptide expressing capability of the mammal is destroyed and/or replaced with the expression system defined above. The invention further relates to a transgenic non-human mammal such as a mouse, rat, rabbit, goat, sheep, pig, lama, camel or bovine species whose germ cells and somatic cells contain a DNA sequence as defined above as a result of chromosomal incorporation into the non-human mammalian genome, or into the genome of an ancestor of said non-human mammal.

公开(公告)号：EP1246946A2

公开(公告)日：2002-10-09

申请号：EP01984619.5

申请日：2001-10-26

申请人： Bionaut Pharmaceuticals

发明人： KHODADOUST, Mehran, M.

IPC分类号： C12Q1/68 ,  C12N15/74 ,  C12N15/00 ,  C07H21/04

CPC分类号： C12N15/85 ,  C12N2800/30 ,  C12N2800/60 ,  C12N2830/003 ,  C12N2840/206 ,  C12N2840/44 ,  C12Q1/6897

摘要： Methods and vectors are disclosed for discovering intracellular regulatory pathways utilized by specific stimulatory agents. Suitable stimulatory agents include cytokines, chemical agents, and antibodies. Cell lines and regulatory factors are provided for screening libraries of drug candidates to identify potential therapeutic agents. Methods and compositions are also provided for identifying genes which are necessary for, or capable of, up regulating or down regulating the targeted genomic loci in the selected cells.

公开(公告)号：EP1203819A3

公开(公告)日：2002-08-07

申请号：EP01120916.0

申请日：2001-08-30

申请人： TRANSGENE S.A.

发明人： Rooke, Ronald

IPC分类号： C12N15/861 ,  C12N15/34 ,  C07K14/075 ,  C12N7/01 ,  C12N5/10 ,  A61K48/00 ,  A61K39/235 ,  A61K31/70

CPC分类号： C12N15/86 ,  A61K39/00 ,  A61K48/00 ,  A61K2039/5256 ,  A61K2039/53 ,  C07K14/005 ,  C12N2710/10322 ,  C12N2710/10343 ,  C12N2830/42 ,  C12N2840/203 ,  C12N2840/44

摘要： The present invention concerns a recombinant adenoviral vector derived from an adenovirus genome in which at least a part of the E3 region is deleted or is non functional, wherein said adenoviral vector retains E3 sequences encoding a functional 14.7K protein, a functional 14.5K protein, and/or a functional 10.4K protein. The present invention further relates to the use of a polynucleotide comprising at least one or more gene(s) of an E3 region of an adenovirus, taken individually or in combination, to protect from an inflammatory reaction in a host cell, tissue or organism. The present invention additionally concerns a viral particle, a host cell and a composition comprising said recombinant adenoviral vector or said polynucleotide, as well as their use for therapeutic or prophylactic purpose.

公开(公告)号：EP1184461A2

公开(公告)日：2002-03-06

申请号：EP01307021.4

申请日：2001-08-17

申请人： Pfizer Products Inc.

发明人： Fisher, Katherine Elizabeth, Pfizer Global Reseach ,  Reaume, Andrew Gerard, Pfizer Global Reseach

IPC分类号： C12N15/64 ,  C12N5/18 ,  A01K67/027 ,  C12N15/85

CPC分类号： C12N15/902 ,  A01K2217/075 ,  C12N2800/102 ,  C12N2840/203 ,  C12N2840/44

摘要： The present invention provides methods of preparing gene targeted mammalian cells having a targeted gene mutation, methods of making gene targeted mice, and gene targeting vectors that are useful in these methods.

摘要翻译： 本发明提供了制备具有目标基因突变的基因靶向的哺乳动物细胞的方法，使得基因靶向的小鼠，和基因靶向载体做的方法是在合成方法是有用的。

公开(公告)号：EP0827547B1

公开(公告)日：2001-08-16

申请号：EP96916528.1

申请日：1996-05-22

申请人： THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES

发明人： BARSOV, Eugene ,  HUGHES, Stephen, H.

IPC分类号： C12N15/86 ,  C12N15/62 ,  C12N7/01 ,  C12N5/10 ,  A01K67/027 ,  A61K39/21 ,  A61K48/00

CPC分类号： C12N15/86 ,  A01K2217/05 ,  A61K48/00 ,  C07K14/005 ,  C07K2319/02 ,  C12N2740/13022 ,  C12N2740/13043 ,  C12N2840/44

摘要： Recombinant avian sarcoma leukosis virus (ASLV)-derived retrovirus vectors having an expanded host range are described. The host range is expanded by the replacement of the ASLV envelope gene by an envelope gene from a virus capable of infecting both mammalian and avian cells. The resulting recombinant ASLV-derived retroviral vectors can replicate efficiently in avian cells, infect both avian and mammalian cells in high titer, and are replication-defective in mammalian cells. Thus, they are quite safe and advantageous for use in gene therapy and vaccines.

公开(公告)号：EP1105513A2

公开(公告)日：2001-06-13

申请号：EP99943690.0

申请日：1999-08-12

申请人： Intronn Holdings LLC

发明人： MITCHELL, Lloyd, G. ,  GARCIA-BLANCO, Mariano, A.

IPC分类号： C12N15/90 ,  A61K48/00 ,  C12N15/11

CPC分类号： C12N15/1027 ,  A61K38/00 ,  A61K48/00 ,  C07K14/34 ,  C07K14/4712 ,  C07K14/59 ,  C12N15/10 ,  C12N15/113 ,  C12N15/63 ,  C12N15/66 ,  C12N15/85 ,  C12N2310/111 ,  C12N2310/12 ,  C12N2840/44 ,  C12N2840/445

摘要： The molecules and methods of the present invention provide a means for in vivo production of a trans-spliced molecule in a selected subset of cells. The pre-trans-splicing molecules of the invention are substrates for a trans-splicing reaction between the pre-trans-splicing molecules and a pre-mRNA which is uniquely expressed in the specific target cells. The in vivo trans-splicing reaction provides a novel mRNA which is functional as mRNA or encodes a protein to be expressed in the target cells. The expression product of the mRNA is a protein of therapeutic value to the cell or host organism a toxin which causes killing of the specific cells or a novel protein not normally present in such cells. The invention further provides PTMs that have been genetically engineered for the identification of exon/intron boundaries of pre-mRNA molecules using an exon tagging method. The PTMs of the invention can also be designed to result in the production of chimeric RNA encoding for peptide affinity purification tags which can be used to purify and identify proteins expressed in a specific cell type.

公开(公告)号：EP1098986A2

公开(公告)日：2001-05-16

申请号：EP99934910.3

申请日：1999-07-21

申请人： Cobra Therapeutics Limited

发明人： ANTONIOU, Michael,Dept. of Experimental Pathology ,  CROMBIE, Robert,Cobra Therapeutics Limited

IPC分类号： C12N15/85 ,  C12N5/10 ,  C12Q1/68 ,  A61K48/00 ,  C12N15/00 ,  A01K67/027 ,  C12N15/11

CPC分类号： C12N15/11 ,  A01K2217/05 ,  A61K48/00 ,  C12N15/63 ,  C12N15/85 ,  C12N2799/027 ,  C12N2800/108 ,  C12N2830/008 ,  C12N2830/205 ,  C12N2830/42 ,  C12N2830/46 ,  C12N2830/85 ,  C12N2840/20 ,  C12N2840/203 ,  C12N2840/44

摘要： The present invention relates to a polynucleotide comprising a ubiquitous chromatin opening element (UCOE) which is not derived from an LCR. The present invention also relates to a vector comprising the polynucleotide sequence, a host cell comprising the vector, use of the polynucleotide, vector or host cell in therapy and in an assay, and a method of identifying UCOEs. The UCOE opens chromatin or maintains chromatin in an open state and facilitates reproducible expression of an operably-linked gene in cells of at least two different tissue types.

公开(公告)号：EP1075531A1

公开(公告)日：2001-02-14

申请号：EP99920375.5

申请日：1999-05-05

申请人： TRANSKARYOTIC THERAPIES, INC.

发明人： TRECO, Douglas, A. ,  HEARTLEIN, Michael, W. ,  SELDEN, Richard, F.

IPC分类号： C12N15/67 ,  C12N15/90 ,  C12N15/85 ,  C12N15/21 ,  C07K14/56 ,  A61K48/00 ,  C12N5/10

CPC分类号： C07K14/56 ,  A61K48/00 ,  C12N15/67 ,  C12N15/85 ,  C12N15/907 ,  C12N2840/44

摘要： An isolated nucleic acid molecule that hybridizes under stringent conditions, or shares at least 80 % sequence identity, with a defined genomic region upstream of the coding region of the IFNA2 gene, and a DNA construct containing that DNA molecule as a targeting sequence for homologous recombination.

摘要翻译： 一种分离的核酸分子并在严格条件下杂交，或共有至少80％序列同一性，与IFNA2基因的编码区上游的限定基因组区域，和一个DNA构建体包含做DNA分子作为用于同源重组靶向序列 ，

公开(公告)号：EP1036177A1

公开(公告)日：2000-09-20

申请号：EP98960546.4

申请日：1998-11-25

申请人： THE IMMUNE RESPONSE CORPORATION

发明人： ILL, Charles, R. ,  GONZALES, Jose, E., N. ,  YANG, Claire, Q. ,  BIDLINGMAIER, Scott

IPC分类号： C12N15/12 ,  C12N15/67 ,  C12N15/85 ,  C07K14/755 ,  A61K48/00

CPC分类号： C07K14/755 ,  A61K48/00 ,  C12N15/67 ,  C12N15/85 ,  C12N2830/008 ,  C12N2830/30 ,  C12N2830/42 ,  C12N2830/48 ,  C12N2830/85 ,  C12N2840/44 ,  C12N2840/445

摘要： Novel genes and vectors exhibiting increased expression and novel splicing patterns are disclosed. The gene can comprise one or more consensus or near consensus splice sites which have been corrected. The gene can alternatively or additionally comprise one or more introns within coding or noncoding sequences. The gene can still further comprise modified 5' and/or 3' untranslated regions optimized to provide high levels and duration of tissue-specific expression. In one embodiment, the gene comprises the coding region of a full-length Factor VIII gene modified by adding an intron within the portion of the gene encoding the β-domain, so that the gene is expressed as a β-domain deleted Factor VIII protein. The novel Factor VIII gene can also be modified to correct one or more consensus or near consensus splice sites within or outside of the coding region.

公开(公告)号：EP1030927A1

公开(公告)日：2000-08-30

申请号：EP98957671.5

申请日：1998-11-09

申请人： Valentis Inc.

发明人： LEDEBUR, Harry, C., Jr. ,  NORDSTROM, Jeffrey, L.

IPC分类号： C12N15/86 ,  A61K39/00

CPC分类号： A61K39/00 ,  A61K2039/51 ,  A61K2039/53 ,  C12N15/85 ,  C12N2830/42 ,  C12N2840/203 ,  C12N2840/44

摘要： Improved plasmids and methods for nucleic acid-based vaccines. The use of epitopes, small immunologically relevant protein sequences that are capable of inducing both cellular and humoral responses that result in a protective or therapeutic immune response against large and complex pathogens for incorporation into nucleic acid-based vaccines. The structures and characteristics of gene expression systems that are capable of expressing multiple epitopes. A method of genetic immunization comprising the step of presenting multiple epitopes to an organism in need of said immunization. A plasmid for expression of multiple epitopes comprising a nucleic acid sequence encoding multiple epitopes, wherein each of said epitopes is capable of creating an immune response. A multivalent expression system as shown in Figure 8 and selected from the group consisting of two plasmids, two genes, IRES, and alternative splicing and a method of making a plasmid producing the appropriate nucleic acid sequence.